top of page
Search

Illuminating Hope: Near-Infrared Therapy's Impact on Mitochondria in Parkinson's Patients

Updated: Apr 6, 2024



Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain. Emerging research suggests that near-infrared therapy (NIRT) could hold promise as a non-invasive and potentially effective treatment for PD. One of the key areas where NIRT shows promise is in its impact on mitochondria, the powerhouse of our cells, in Parkinson's patients.


Mitochondrial Dysfunction in Parkinson's Disease


Mitochondria are tiny structures within our cells responsible for producing adenosine triphosphate (ATP), the cell's primary energy source. In PD, mitochondrial dysfunction is a critical factor contributing to the degeneration of dopaminergic neurons. Dysfunctional mitochondria produce less ATP and generate harmful reactive oxygen species (ROS) that damage cells, including neurons. Therefore, any therapy that can improve mitochondrial function may have a profound impact on the progression of PD.


Near-Infrared Therapy: Shedding Light on Mitochondria


NIRT, also known as photobiomodulation, involves the exposure of tissues to low-level near-infrared light. This light penetrates the skin and stimulates various cellular processes, including those within mitochondria. Here's how NIRT may benefit Parkinson's patients:


1. Enhanced ATP Production: Near-infrared light has been shown to boost ATP production within mitochondria. By providing more energy to cells, NIRT may help support the energy-intensive functions of neurons, potentially slowing down their degeneration in PD.


2. Reduction of Oxidative Stress: NIRT can reduce the production of harmful ROS within mitochondria. In Parkinson's, the accumulation of ROS contributes to neuronal damage. By mitigating oxidative stress, NIRT may protect neurons from further harm.


3. Anti-Inflammatory Effects: Chronic inflammation is a hallmark of Parkinson's disease. NIRT has anti-inflammatory properties that can potentially reduce neuroinflammation, thus preserving dopaminergic neurons.


4. Enhanced Neuroprotection: NIRT may activate cellular pathways that promote neuroprotection and cell survival. This could help neurons withstand the stressors associated with PD.


Promising Studies and Clinical Trials


While research on NIRT for Parkinson's is still in its early stages, several studies have shown promising results. Animal studies have demonstrated improved motor function and reduced neuronal damage following NIRT treatment. Additionally, a small clinical trial involving PD patients reported improved motor symptoms and a reduction in oxidative stress markers after NIRT sessions.


Parkinson's disease is a complex condition with no cure at present, but the potential of near-infrared therapy to impact mitochondrial function offers hope for patients and researchers alike. By enhancing ATP production, reducing oxidative stress, and combating inflammation, NIRT may slow the progression of PD and improve patients' quality of life. However, further research and larger clinical trials are needed to fully understand NIRT's potential and establish it as a safe and effective therapy for Parkinson's patients. As science continues to shed light on this promising treatment, it brings a glimmer of hope to those affected by this challenging neurodegenerative disease.

 
 

'Living well naturally with Parkinson's until there is a cure.'

  • MacuDopa Facebook page
  • MacuDopa Twitter X Account

*Disclaimer UK

​This website is for customers in the United States of America and worldwide ONLY. If you are a UK citizen looking to buy Macudopa please visit our UK site.

All the information included on this website is for information purposes only. It is not intended to treat or diagnose any medical condition, nor is it intended as a substitute for medical advice. We do not suggest using Mucuna pruriens to treat Parkinson's unless prescribed by your medical professional. If you are concerned about any symptoms please visit your doctor for investigation and diagnosis. For medical diagnosis and treatment please consult your specialist or doctor. The statements regarding Mucuna have not been evaluated by the Food and Drug Administration. These product is not intended to diagnose, treat, cure, or prevent any disease.

© 2025 CogniBrain LTD. All rights reserved.

The content provided in connection with MacuDopa, including but not limited to text, product descriptions, research summaries, FAQs, and proprietary information regarding our Mucuna-based formulation, is protected under copyright law. Unauthorized use, reproduction, or distribution of any part of this content is prohibited without prior written permission from CogniBrain LTD. MacuDopa and related intellectual property are the sole property of CogniBrain LTD, and any infringement will be pursued to the fullest extent permitted by law.

bottom of page